HIV Infections
Conditions
Keywords
HIV-1 Infection, HIV Seronegativity
Brief summary
IPM 012 is a double-blind, randomized, placebo-controlled phase I study conducted at one research center in Belgium among 36 healthy, HIV-negative women of 18-40 years of age, randomized in a 1:1:1 ratio to assess plasma, vaginal fluid and vaginal tissue levels and the pharmacokinetics of dapivirine when applying either Dapivirine Gel 4750, 0.05%, 2.5g or Dapivirine Gel 4789, 0.05%, 2.5g intravaginally for 11 days (1 day followed by a 3 day washout period and then 10 consecutive days); and to assess the safety of these gels as compared to the intravaginal HEC-based universal placebo gel.
Interventions
DRUGDapivirine Gel 4750, 0.05%, 2.5g
intravaginal gel, dosed daily
DRUGDapivirine Gel 4789, 0.05%, 2.5g
intravaginal gel, dosed daily
DRUGHEC-based Placebo Gel
intravaginal gel, dosed daily
Sponsors
International Partnership for Microbicides, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Women between 18 and 40 years of age, inclusive * Willing and able to give written informed consent * Available for all visits and consent to follow all procedures * Healthy, based on medical history, vital signs, physical examination, urinalysis, laboratory evaluations for genital infections and laboratory evaluations for hematology, liver and renal function * HIV-negative as determined by a HIV-1 ELISA test at enrollment * Willing to abstain from sexual activity for the duration of the study * On stable oral contraceptive regimen for 2 months prior to enrollment and willing to continue * Upon pelvic/speculum examination, the cervix and vagina appear normal * Willing to refrain from the use of vaginal products from 14 days prior to enrollment and for the duration of the study
Exclusion criteria
* History of alcoholism, drug abuse, psychosis, antagonistic personality, poor motivation or other emotional or intellectual problems that are likely to invalidate the informed consent process or adversely impact adherence with protocol requirements * History of sensitivity/allergy to any component of the study product or to latex * Currently pregnant or breast-feeing, or within 3 months of last pregnancy outcome * Currently or within one month of participating in any other clinical research study * History or current diagnosis and/or treatment for a STD within the last three months prior to enrollment * Current vulvar, vaginal or cervical symptoms/abnormalities as determined by pelvic/speculum exam or colposcopy that could influence the study results * History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding or urethral obstruction within the last 3 months * Current non-iatrogenic pelvic/colposcopic exam findings involving deep epithelial disruption * Smoking more than 10 cigarettes a day
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serial dapivirine concentrations in plasma, vaginal fluid and cervical-vaginal tissue samples | 11 days |
| Self-reported genital symptoms, pelvic/colposcopic exam findings, laboratory evaluations and adverse events/serious adverse events | 14 days |
Countries
Belgium
Outcome results
None listed